Synact ready for phase II with arthritis candidate: "An important milestone for the company"

After finishing phase I trials, Danish biotech company Synact has applied for the authorities' permission to initiate a phase II study with the company's lead candidate against rheumatoid arthritis. According to the CEO, the company has various financing opportunities.

Foto: Synact Pharma PR

Danish biotech company Synact Pharma, which went public in Sweden in 2016, has applied for permission from Danish Medicines Agency and the National Committee on Health Research Ethics to initiate a larger phase II study with AP1189 - the company's candidate for treatment of rheumatoid arthritis.

"Our goal was to take AP1189 to phase II of the clinical development, so this is an important milestone for the company, which we have worked towards for most of 2018," says Jeppe Øvlesen, CEO in Synact Pharma, to MedWatch.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Trial banner

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier